MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599093 | Name: Fluindione
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluindione is a hematologic agent.

Chemical Structure

Fluindione
Fluindione
CAS#957-56-2

Theoretical Analysis

MedKoo Cat#: 599093

Name: Fluindione

CAS#: 957-56-2

Chemical Formula: C15H9FO2

Exact Mass: 240.0587

Molecular Weight: 240.23

Elemental Analysis: C, 75.00; H, 3.78; F, 7.91; O, 13.32

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Fluindione; Fluindiona; Fluindionum; Previscan; LM 123; LM-123; LM123;
IUPAC/Chemical Name
2-(4-fluorophenyl)-1H-indene-1,3(2H)-dione
InChi Key
NASXCEITKQITLD-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H9FO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H
SMILES Code
O=C1C(C2=CC=C(F)C=C2)C(C3=C1C=CC=C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 240.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V. A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone. Thromb Haemost. 2014 Apr 1;111(4):705-12. doi: 10.1160/TH13-07-0555. Epub 2013 Dec 12. PubMed PMID: 24337438. 2: Pautas É, Peyron I, Gouin-Thibault I, Gouronnec A, Monti A, Bouhadiba S, Badie C, Golmard JL, Siguret V. [Relationship between maintenance dosages of fluindione (Préviscan) and warfarin (Coumadin) for patients 70 years and older]. Rev Med Interne. 2015 Jan;36(1):7-9. doi: 10.1016/j.revmed.2013.11.017. Epub 2013 Dec 27. French. PubMed PMID: 24373728. 3: Peyro Saint Paul L, Martin J, Moslemi I, Le Hello C, Le Querrec A. [Warfarin switch from fluindione in elderly patients]. Presse Med. 2014 Feb;43(2):221-3. doi: 10.1016/j.lpm.2013.06.018. Epub 2013 Nov 1. French. PubMed PMID: 24184283. 4: Imbert P, Pernod G, Jacquet JP, Bailly C, Laporte S, Lievre M; Investigators of INRPlus Study Group. Evaluation of a mobile electronic assistant to aid in fluindione prescription: the INRPlus cluster randomized trial. Thromb Res. 2014 May;133(5):756-61. doi: 10.1016/j.thromres.2014.02.003. Epub 2014 Feb 11. PubMed PMID: 24582071. 5: Bauduer F. Uneventful long-term anticoagulation with fluindione in a patient with severe factor XI deficiency. Haemophilia. 2015 Jan;21(1):e72-3. doi: 10.1111/hae.12502. Epub 2014 Nov 24. PubMed PMID: 25421862. 6: Crepin T, Bamoulid J, Courivaud C, Dahmani O, Felix S, Ducloux D. Reversible Fluindione-Induced Chronic Interstitial Nephritis. Case Rep Nephrol. 2016;2016:9818195. doi: 10.1155/2016/9818195. Epub 2016 Apr 5. PubMed PMID: 27127666; PubMed Central PMCID: PMC4835627. 7: Cam G, Kwetcheu AT, Vigneau C, Siohan P, Queffeulou G, Gatault P, Laruelle E, Crémault A, Le Cacheux P, Rioux-Leclercq N, Renaudineau E. Acute and chronic nephropathy induced by fluindione must be addressed. Nephrol Dial Transplant. 2012 Apr;27(4):1554-8. doi: 10.1093/ndt/gfr500. Epub 2011 Sep 19. PubMed PMID: 21931126. 8: Comets E, Diquet B, Legrain S, Huisse MG, Godon A, Bruhat C, Chauveheid MP, Delpierre S, Duval X, Berrut G, Verstuyft C, Aumont MC, Mentré F. Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians. Clin Pharmacol Ther. 2012 May;91(5):777-86. doi: 10.1038/clpt.2011.309. PubMed PMID: 22472992; PubMed Central PMCID: PMC3789273. 9: Daveluy A, Milpied B, Barbaud A, Lebrun-Vignes B, Gouraud A, Laroche ML, Ciobanu E, Bégaud B, Moore N, Miremont-Salamé G, Haramburu F; French Pharmacovigilance Centres Network and The Toxidermia Group of the French Society of Dermatology. Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect? Eur J Clin Pharmacol. 2012 Jan;68(1):101-5. doi: 10.1007/s00228-011-1101-9. Epub 2011 Jul 27. PubMed PMID: 21792562. 10: Farnier E, Charhon N, Papillon L, Tod M. [Interaction between Amoxicillin Clavulanic Acid and Fluindione: Two Case Reports]. Therapie. 2015 Nov 6. [Epub ahead of print] French. PubMed PMID: 26544165. 11: Lacut K, Ayme-Dietrich E, Gourhant L, Poulhazan E, Andro M, Becquemont L, Mottier D, Le Gal G, Verstuyft C. Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol. 2012 Mar;73(3):428-36. doi: 10.1111/j.1365-2125.2011.04095.x. PubMed PMID: 21883387; PubMed Central PMCID: PMC3370347. 12: Beqqal K, Horellou MH, Philippe A, Alhene Gelas M, Flaujac C, Gorin I, Jacobelli S, Dupin N, Hassam B, Avril MF. Skin necrosis due to fluindione treatment: a rare but serious complication. J Wound Care. 2014 Feb;23(2 Suppl):S16-9. PubMed PMID: 24526169. 13: Verstuyft C, Delavenne X, Rousseau A, Robert A, Tod M, Diquet B, Lebot M, Jaillon P, Becquemont L. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy. Clin Pharmacokinet. 2012 Jan 1;51(1):41-53. doi: 10.2165/11595560-000000000-00000. PubMed PMID: 22149257. 14: Ngo S, Benhamou Y, Armengol G, Sauvêtre G, Cailleux-Talbot N, Massy N, Buchonnet G, Lévesque H. [Agranulocytosis related to fluindione: A case report]. Rev Med Interne. 2016 Jan;37(1):58-61. doi: 10.1016/j.revmed.2015.05.013. Epub 2015 Jun 18. French. PubMed PMID: 26096756. 15: Ayme-Dietrich E, Aubertin-Kirch G, Andrès E, Monassier L. [Esomeprazole-induced resistance to fluindione: An unrecognized interaction]. Therapie. 2016 Jun;71(3):337-41. doi: 10.1016/j.therap.2016.02.023. Epub 2016 Feb 11. French. PubMed PMID: 27235659. 16: Immunoallergic adverse effects of fluindione. Prescrire Int. 2010 Nov;19(110):255-6. Review. PubMed PMID: 21284358. 17: Farnier E, Charhon N, Papillon L, Tod M. [Interaction between amoxicillin clavulanic acid and fluindione: Two case reports]. Therapie. 2016 Oct 19. pii: S0040-5957(16)30056-7. doi: 10.2515/therapie/2015059. [Epub ahead of print] French. PubMed PMID: 27771106. 18: Merklen-Djafri C, Mazurier I, Samama MM, Alhenc-Gelas M, Tortel MC, Cribier B, Roth B, Batard ML. [Skin necrosis during long-term fluindione treatment revealing protein C deficiency]. Ann Dermatol Venereol. 2012 Mar;139(3):199-203. doi: 10.1016/j.annder.2011.12.018. Epub 2012 Jan 30. French. PubMed PMID: 22401685. 19: Pautas E, Despres J, Peyron I, Golmard JL, Grange J, Koenig N, Gouronnec A, Mitha N, Siguret V, Gouin-Thibault I. [Divisibility of warfarin and fluindione tablets tested in elderly patients and their family circle]. Geriatr Psychol Neuropsychiatr Vieil. 2011 Jun;9(2):171-7. doi: 10.1684/pnv.2011.0269. French. PubMed PMID: 21690025. 20: Thurot C, Reymond JL, Bourrain JL, Pinel N, Beani JC. [Fluindione-induced acute exanthematous pustulosis with renal involvement]. Ann Dermatol Venereol. 2003 Dec;130(12 Pt 1):1146-9. Review. French. PubMed PMID: 14724519.